StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) company profile

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

About Ultragenyx Pharmaceutical

Pharmaceutical Preparations, SIC 2834

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company engaged in the identification, acquisition, development, and commercialization of therapeutic products. Its business centers on treatments for serious medical conditions, with commercial products and collaborations that include therapies such as Crysvita, Dojolvi, Mepsevii, and Evkeeza. The organization collaborates with biopharmaceutical partners and institutions to advance research, clinical development, licensing arrangements, and product distribution.

The company operates in North America and engages in commercial, licensing, and development activities across international regions, including Latin America, Europe, the Middle East, and the Asia-Pacific territory. It maintains facilities for research, development, and manufacturing. Ultragenyx Pharmaceutical Inc. is organized under the laws of Delaware and maintains its principal executive offices in Novato, California.

Summary of the business section of Ultragenyx Pharmaceutical's latest annual report, written by StockData.

Company profile

Company

Legal name
Ultragenyx Pharmaceutical Inc.
Founded
2010
Headquarters
Novato, CA
Address
60 Leveroni Court 94949
Phone
(415) 483-8800
Employees
1,371, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
RARE
Exchange
Nasdaq
IPO date
Jan 31, 2014
Shares outstanding
99M, Jul 31, 2026
Public float
$3.40B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1515673
CUSIP
90400D108
ISIN
US90400D1081
FIGI
BBG001RWPDW6
Share class FIGI
BBG001V2MJJ2
LEI
529900EV44GVDN1DCX77
EIN
27-2546083

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Emil D. KakkisPresident & CEO, Director2,694,724
Howard HornChief Financial Officer89,229
Theodore Alan HuizengaSVP, Chief Accounting Officer67,863
Karah Herdman ParschauerEVP and Chief Legal Officer92,562
Eric CrombezEVP and Chief Medical Officer111,189
John Richard PinionSee Remarks133,142
Dennis Karl HuangSee Remarks147,845
Erik HarrisEVP & Chief Commercial Officer118,410
Thomas Richard KassbergCBO & EVP265,238
Corazon (Corsee) D. SandersDirector21,095
Daniel G. WelchDirector40,441
Michael NarachiDirector40,441
Deborah DunsireDirector38,566
Amrit RayDirector31,116
Shehnaaz SulimanDirector27,951
Matthew K. FustDirector33,696

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$11.41M-$1.29M$3.83M$17$120
FY2024$13.72M$8.19M$4.25M$30$91
FY2023$13.08M$11.29M$4.52M$35$92
FY2022$12.14M$3.31M$3.91M$33$89
FY2021$9.52M-$2.15M$3.31M$61$99
FY2020$5.14M$22.73M$2.71M$324$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Emil D. Kakkis, M.D., Ph.D.
President and Chief Executive Officer
$861.10K$8.36M$1.85M$299.66K$32.48K$11.41M-17%
Howard Horn
Chief Financial Officer, Corporate Strategy and Executive Vice President
$604.39K$2.24M$663.13K$227.63K$14.00K$3.75M-13%
Erik Harris
Chief Commercial Officer and Executive Vice President
$619.69K$2.41M$712.26K$291.56K$14.00K$4.05M-6%
Eric Crombez, M.D.
Chief Medical Officer and Executive Vice President
$630.23K$2.41M$712.26K$238.13K$14.00K$4.00M-7%
Karah Parschauer
Chief Legal Officer and Corporate Affairs, Executive Vice President
$585.34K$2.08M$614.01K$220.53K$14.00K$3.51M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 31, 2014
Offer price
$21.00
Securities offered
5,760,369
Gross proceeds
$120.97M
Exchange
Nasdaq
First trading day
Jan 31, 2014
First-day close
$42.25+101.2%
Lock-up ends (est.)
Jul 30, 2014

“The initial public offering price is $21.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 1,371 total employees, of which 916 are in research and development and 455 are in sales, general, and administrative.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?